None listed
Conditions
Brief summary
Allergic rhinitis is a common condition characterized by nasal allergy symptoms. This study aims to compare the effectiveness of topical corticosteroids and systemic antihistamines in relieving symptoms. The objective is to determine which treatment offers better short-term and long-term symptom control to guide optimal management strategies.
Interventions
Two intervention groups were studied. One group received fexofenadine only, and the other group received budesonide only. Fexofenadine was administered orally as a tablet once daily at a dose of 120 mg for participants younger than 18 years and 180 mg for participants aged 18 years or older. Budesonide was administered intranasally at a dose of 32 mcg per spray, with two sprays in each nostril twice daily. Both medications were administered for a duration of one month. No specific strategies wer
Two intervention groups were studied. One group received fexofenadine only, and the other group received budesonide only. Fexofenadine was administered orally as a tablet once daily at a dose of 120 mg for participants younger than 18 years and 180 mg for participants aged 18 years or older. Budesonide was administered intranasally at a dose of 32 mcg per spray, with two sprays in each nostril twice daily. Both medications were administered for a duration of one month. No specific strategies were used to monitor adherence to the intervention.
Sponsors
Damascus University
Study design
Allocation
Randomised controlled trial
Primary purpose
Treatment
Eligibility
Sex/Gender
All
Age
12 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
The inclusion criteria were patients aged between 12 and 60 years, with a clinical diagnosis of seasonal allergic rhinitis, and a willingness to participate and provide informed consent.
Exclusion criteria
The exclusion criteria were inability to follow up, age below 12 or above 60, other types of nasal inflammations, contraindications to any of the study medications, non-adherence to treatment for a minimum of 25 days, as well as a history of asthma, nasal polyps, or obstructive nasal septum deviation.
Outcome results
None listed